What can duchenne connect teach us about treating duchenne muscular dystrophy?

Current Opinion in Neurology

Volumn 28, Issue 5, 2015, Pages 535-541

  Wang, Richard T ^a   Nelson, Stanley F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Becker muscular dystrophy; Duchenne muscular dystrophy; Online Registries; Patient reported outcomes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARNITINE; CORTICOSTEROID; CREATINE; DEFLAZACORT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDROXYCORTIDE; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; HUMAN GROWTH HORMONE; IDEBENONE; INOSITOL; MAGNESIUM; MELATONIN; PHOSPHATIDYLCHOLINE; PREDNISONE; RESVERATROL; RETINOL; SILDENAFIL; TAURINE; THIOCTIC ACID; UBIDECARENONE; VITAMIN; VITAMIN B COMPLEX; VITAMIN D;

ALTERNATIVE MEDICINE; BECKER MUSCULAR DYSTROPHY; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE REGISTRY; DUCHENNE MUSCULAR DYSTROPHY; HEALTH SURVEY; HUMAN; INDEL MUTATION; MUTATIONAL ANALYSIS; ONLINE MONITORING; OUTCOME ASSESSMENT; PATIENT INFORMATION; PATIENT MONITORING; QUESTIONNAIRE; REVIEW; SELF REPORT; SUPPLEMENTATION; THERAPY EFFECT; VITAMIN SUPPLEMENTATION; GENETICS; MUSCULAR DYSTROPHY, DUCHENNE; PATIENT PARTICIPATION; REGISTER;

HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; PATIENT PARTICIPATION; REGISTRIES;

EID: 84941774665     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000245     Document Type: Review

References (27)

1. Rangel V, Martin AS, Peay HL. duchenne connect registry report. PLoS Curr 2012; 4:1-10.
2. Johnson KJ, Mueller NL, Williams K, Gutmann DH. Evaluation of participant recruitment methods to a rare disease online registry. Am J Med Genet A 2014; 164A:1686-1694.
3. Need AC, Shashi V, Hitomi Y, et al. Clinical application of exome sequencing in undiagnosed genetic conditions. J Med Genet 2012; 49:353-361.
4. Arboleda VA, Lee H, Dorrani N, et al. De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay. Am J Hum Genet 2015; 96:498-506.
5. Scully MA, Cwik VA, Marshall BC, et al. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Neurology 2013; 80:583-589.
6. Landfeldt E, Lindgren P, Bell CF, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology 2014; 83:529-536.
7. Peay HL, Hollin I, Fischer R, Bridges JFP. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for duchenne muscular dystrophy. Clin Ther 2014; 36:624-637.
8. Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD global database: analysis of more than 7000 duchenne muscular dystrophy mutations. Hum Mutat 2015; 36:395-402.
9. Mah JK, Korngut L, Dykeman J, et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 2014; 24:482-491.
10. Romitti PA, Zhu Y, Puzhankara S, et al. Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics 2015; 135:513-521.
11. Wang RT, Silverstein Fadlon CA, Ulm JW, et al. Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS Curr 2014; 6:1-14.
12. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34:135-144.
13. Tuffery-Giraud S, Beroud C, Leturcq F, et al. Genotype-phenotype analysis in 2405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 2009; 30:934-945.
14. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2:90-95.
15. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10:1547-1554.
16. Mendell J, Moxley R, Griggs R, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989; 320:1592-1597.
17. Griggs RC, Moxley RT III, Mendell JR, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Arch Neurol 1991; 48:383-388.
18. Moxley RT 3rd, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64:13-20.
19. Bushby K, Muntoni F, Urtizberea A, et al. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Dis 2004; 14:526-534.
20. Griggs RC, Herr BE, Reha A, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 2013; 48:27-31.
21. Merlini L, Gennari M, Malaspina E, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012; 45:796-802.
22. Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001; 138:45-50.
23. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000; 23:1344-1347.
24. Bello L, Gordish Dressman HA, Morgenroth L, et al. Prednisone/prednisolone and deflazacort differ in long term outcomes on ambulation and side effects in the CINRG Duchenne Natural History Study. Neurology 2015; 84 (Suppl): 1526-1632.
25. Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011; 77:444-452.
26. Spurney CF, Rocha CT, Henricson E, et al. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve 2011; 44:174-178.
27. Schork NJ. Personalized medicine: time for one-person trials. Nature 2015; 520:609-611.